Screening for SARS-CoV-2 by RT-PCR: saliva or nasopharyngeal swab?

Systematic review and meta-analysis.

Nusaïbah Ibrahimi¹, Agnès Delaunay-Moisan², Catherine Hill¹, Gwénaél Le Teuff¹, Jean-François Rupprecht³, Jean-Yves Thuret², Dan Chaltiel^{1*}, and Marie-Claude Potier^{4*}.

¹ Unité de Biostatistiques et d'Épidémiologie, Institut Gustave Roussy, 39, rue Camille Desmoulins, 94805 Villejuif Cedex, France.

² Université Paris-Saclay, CEA, CNRS, Institute for Integrative Biology of the Cell (I2BC), 91198, Gif-sur-Yvette cedex, France.

³ Aix Marseille Univ, CNRS, Centre de Physique Théorique, Turing Center for Living Systems, Marseille, France.

⁴ Institut du Cerveau (ICM), CNRS UMR 7225 – Inserm U1127, Sorbonne Université, Paris, France.

* co-corresponding authors:

marie-claude.potier@upmc.fr

dan.chaltiel@gustaveroussy.fr

Abstract: 244 words

Main text: 2047 words

References: 86

1 Table

4 Figures

Appendix: Figures S1, S2 and S3

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract

Diagnosis of COVID-19 in symptomatic patients and screening of populations for SARS-CoV-2 infection require access to straightforward, low-cost and high-throughput testing. The recommended nasopharyngeal swab tests are limited by the need of trained professionals and specific consumables and this procedure is poorly accepted as a screening method. The use of alternative validated samples such as saliva is thus much awaited.

In order to compare saliva and nasopharyngeal/oropharyngeal samples for the detection of SARS-CoV-2, we designed a meta-analysis searching in PubMed up to December 29th, 2020 with the key words “((SARS-CoV-2 OR COVID-19) AND (saliva OR oral fluid)) NOT (review[Publication Type])” applying the following criteria: records published in peer reviewed scientific journals, in English, with at least 15 nasopharyngeal/oropharyngeal swabs and saliva paired samples tested by RT-PCR, studies with available raw data including numbers of positive and negative tests with the two sampling methods. For all studies, concordance and sensitivity were calculated and then pooled in a random-effects model.

A total of 318 studies were retrieved, of which 49 were eligible, reporting on 16,272 pairs of nasopharyngeal/oropharyngeal and saliva samples. Meta-analysis showed high concordance, 92.6% (95%CI: 89.6-94.8), across studies and pooled sensitivities of 86.7% (95%CI: 83.5-89.3) and 92.2 (95%CI: 89.4-94.4) from saliva and nasopharyngeal/oropharyngeal swabs respectively. Heterogeneity across studies was 80.0% for saliva and 84.0% for nasopharyngeal/oropharyngeal swabs.

Our meta-analysis strongly suggests that saliva could be used for frequent testing of COVID-19 patients and “en masse” screening of populations.

Author summary

Why was this study done?

Three published meta-analysis comparing SARS-CoV-2 loads in paired saliva and nasopharyngeal samples included only 4, 5 and 16 studies up to December 29th, 2020. We thus searched additional studies in PubMed with the key words “((SARS-CoV-2 OR COVID-19) AND (saliva OR oral fluid)) NOT (review[Publication Type])” applying the following criteria: records published in peer reviewed scientific journals, in English, with at least 15 saliva and nasopharyngeal/oropharyngeal paired samples tested by RT-PCR, studies with available raw data including numbers of positive and negative tests with the two sampling methods.

What did the researchers do and find?

Forty-nine published studies were eligible, reporting on 16,272 pairs of saliva and nasopharyngeal/oropharyngeal samples. Our unprecedented meta-analysis showed high concordance (92.6%) across studies and pooled sensitivities of 86.7% and 92.2% from saliva and nasopharyngeal/oropharyngeal swabs respectively.

What do these findings mean?

Sensitivity of SARS-CoV-2 RT-PCR detection in saliva samples is above the 80% sensitivity cut-off recommended by health regulatory authorities. Our meta-analysis validates the use of saliva sample for mass screening to combat the COVID-19 pandemic.

Introduction

Propagation of infections by SARS-CoV-2, the coronavirus causing the COVID-19 pandemic, occurs from asymptomatic as well as symptomatic carriers¹. To reduce the circulation of the virus in the population, SARS-CoV-2 carriers need to be identified rapidly and isolated as soon as possible, ideally before the onset of symptoms. When the virus has disseminated throughout a whole country, massive testing becomes of utmost urgent importance to combat the pandemic²⁻⁴.

The recommended diagnosis of SARS-CoV-2 infection from the World Health Organisation is based on real time RT-qPCR detection of viral RNA in respiratory specimen such as nasopharyngeal swabs (NP), bronchial aspiration (BA), throat swab and sputum⁵. The American Centres For Disease Control and Prevention and the European Centre for Disease Prevention and Control now recommend viral testing from the respiratory system such as nasal or oral swabs or saliva^{6,7}. Currently, the French health regulatory authority (*Haute Autorité de Santé*)⁸ only supports saliva samples for the detection of SARS-CoV-2 on symptomatic individuals.

To make the diagnostic acceptable to the greatest number of people, especially asymptomatic, massive testing should be based on a sampling procedure that is inexpensive, easy to set up and well accepted by the population⁹. In contrast to nasopharyngeal swabbing, saliva sampling meets these criteria. Saliva sampling is fast, non-invasive, inexpensive and painless. It does not require trained professional and personal protective equipment nor other material than simple plastic tube, and can be self-administered.

To evaluate saliva sampling for the detection of SARS-CoV-2, we conducted a meta-analysis on studies published in peer-reviewed journals until the 29th of December 2020 comparing the detection of SARS-CoV-2 using RT-PCR on paired nasopharyngeal/oropharyngeal and saliva samples in the same individuals sampled at the same time.

Methods

Search Strategy and selection criteria

Literature search in PubMed (<https://pubmed-ncbi-nlm-nih-gov>) run the 29th of December 2020 with search word ((SARS-CoV-2 OR COVID-19) AND (saliva OR oral fluid)) NOT (review[Publication Type]) identified 315 articles. We included publications if they met the following eligibility criteria:

- 1) Records published in peer reviewed scientific journals;
- 2) Records published in English;
- 3) Data curation based on examination of the titles and abstract, searching for research articles assessing viral RNA presence in saliva vs nasopharyngeal and/or oropharyngeal swabs;
- 4) Availability of nasopharyngeal (and/or oropharyngeal) swabs and saliva data on specimens sampled on the same individuals at the same time;
- 5) Detection of SARS-CoV-2 using the same RT-PCR method on both samples;
- 6) More than 15 individuals included in the study.

Data analysis

From each eligible article, we extracted: the number of individuals positive for SARS-CoV-2 in both nasopharyngeal/oropharyngeal swabs and saliva (a), those positive only in nasopharyngeal/oropharyngeal swab (b), those positive only in saliva (c) and (d) those negative in both nasopharyngeal swab and saliva (**Table 1**). All articles where we highlighted the extracted data are available on the following link¹⁰. From these data, we calculated the concordance of the same test (RTqPCR for 48 studies and RTdPCR for 1 study) on the two types of sample $(a+d)/(a+b+c+d)$. We also computed the sensitivity of the test on each type of sample. The estimation of the sensitivity of a test requires a reference diagnosis. Since nasopharyngeal swab sampling has been shown to produce false negatives by RTqPCR¹¹, sensitivities for the saliva and the nasopharyngeal swab are defined here respectively as $(a+c)/(a+b+c)$ and $(a+b)/(a+b+c)$, considering as true positive any individual with a positive result on one or the other sample. This definition of a positive individual is also in agreement with the US-CDC and the ECDC directives on SARS-Cov-2 testing,

The overall concordance and sensitivities have been estimated in a meta-analysis via Generalized Linear Mixed Models (GLMM)^{12,13}, using a fixed-effect model, and also a random-effect model in case of an over dispersion of the observations. Dispersion of effect sizes was evaluated using the Higgins I^2 estimate of heterogeneity along with the Cochran's Q in fixed-effect models¹⁴ and using the tau² estimate (between-study variance which is the variance of the distribution of true effect size) in random-effects models. The tau² was calculated using the maximum likelihood estimator. As some studies have a sample size too small for the normality hypothesis, confidence intervals for each study were computed using the Clopper-Pearson method¹⁵ also called "exact" binomial interval.

Those for the overall estimates are based on normal approximation. Results are presented as forest plots.

All analyses were done with R version 4.0.3, using the package “meta” version 4.15-1 (2020-09-30) ^{16,17}.

Results

Forty-six studies comparing SARS-CoV-2 loads in NP swabs and saliva samples collected concurrently in the same individuals using the same technique and providing positivity and negativity in both samples have been identified in PubMed¹⁸⁻⁶³. We also included 3 articles not identified in the original Pubmed keywords search while fulfilling eligibility criteria (**Table 1 and Figure 1**)⁶⁴⁻⁶⁶. In total 16,272 paired samples were analysed. The number of paired samples per study varied between 16 and 3834. Meta-analysis showed an overall concordance of 92.6% (95%CI: 89.6-94.8) across studies (**Figure 2**).

The overall sensitivity of the RTqPCR test from saliva samples was 86.7% (95%CI: 83.5-89.3) (**Figure 3**) versus 92.2% from nasopharyngeal swabs (95%CI: 89.4-94.8) (**Figure 4**). There was no association between the sensitivities of the saliva (**Figure S1**) or of nasopharyngeal swab (**Figure S2**) estimated in each study and the prevalence of the virus in the same study. If the sensitivity of the saliva was lower in populations of asymptomatic individuals than in population of individuals with symptoms, one would expect to observe a lower sensibility of the saliva in the studies with a low prevalence.

In our fixed-effect model meta-analysis, saliva gave I^2 of 80% and nasopharyngeal gave I^2 of 84%, both corresponding to high heterogeneity. Therefore, a random-effect model was performed to assess the overall sensitivities of the RTqPCR tests, taking into account the fact that the studies do not come from one single population. The variance of saliva was 0.51 and that of nasopharyngeal was 1.02. As a sensitivity analysis, we also used various other methods to estimate the sensitivity, the confidence interval and the tau² and all yielded very similar results.

Discussion

This meta-analysis reviewed 49 studies and concluded to a high concordance between nasopharyngeal and saliva samples for the detection of SARS-CoV-2 by RT-PCR. Although sensitivity was slightly lower on saliva samples than on nasopharyngeal samples, both values are above the 80% sensitivity cut-off recommended by health regulatory authorities such as the French Haute Autorité de Santé.

For computing concordance and sensitivities, we considered here the reference as SARS-CoV-2 positivity by RT-PCR either in saliva and/or nasopharyngeal samples since the presence of the virus in any sample is indicative of virus carriage.

In the context of mass screening, most participants are asymptomatic. Among the 49 studies analysed, only one included exclusively asymptomatic participants⁶⁷ and 8 studies both symptomatic and asymptomatic participants but it was impossible to separate the data between the two populations^{18,21,26,29,51,56,64,66}. One study of contact cases included a larger number of asymptomatic subjects as compared to study of symptomatic subjects⁴⁹. We did not observe any difference in concordance of the tests in these particular studies involving asymptomatic participants (**Table 1**). Formal comparison of nasopharyngeal and saliva samples from asymptomatic individuals is challenging: it would require to screen a large population for a small number of positive cases detected since the prevalence is usually low in this population. On the contrary, the symptomatic population expectedly contains higher percentage of positive subjects, as symptoms usually timely correlates with the highest viral load, which allow an easier comparison of both sampling procedures. Anyhow viral load in saliva of presymptomatic subjects remains in the range of detection of the RTqPCR test for several days both in saliva⁶⁸ and nasopharyngeal samples⁶⁹. In addition, both asymptomatic and symptomatic subjects appear to be contagious¹ with similarities in their viral load evolution⁷⁰⁻⁷². Moreover, **Figure S3** shows that in France the proportion of positive cases in the symptomatic tested population is consistently about 5 times that of the asymptomatic tested population, independently of any variation of the viral prevalence over time. This and the fact that neither saliva nor nasopharyngeal sensitivities are affected in a screening-like context (the low prevalence being taken as a proxy, **Figure S1 and S2**) strongly predict that viral detection shall exhibit similar performance in both populations.

Our meta-analysis showed large heterogeneity between studies. Sources of heterogeneity are both biological and technical. Biological heterogeneity may come from the fact that a given individual may carry the virus in only one of the saliva or

nasopharyngeal specimens, or from the timing of sampling during the course of contamination. Technical heterogeneity comes from differences in the sampling and in RT-PCR methods. Among the 49 studies meeting the inclusion criteria for the meta-analysis, 29 studies report saliva collection in sterile containers (urine tubes or vials) without any additional solution. The other studies diluted the saliva in various viral transport media or phosphate buffer saline with or without bovine serum albumin. Other sources of variability come from differences in the amplified region of SARS-Cov-2 or to different positivity threshold between studies; most studies do not present viral load data but only cycle thresholds (Ct) for specific amplification of SARS-Cov-2 sequences and not even Ct differences (Δ Ct) with a human reference gene.

Altogether, our meta-analysis of 49 studies including 16,272 paired samples shows high concordance (92.6%) between nasopharyngeal/oropharyngeal swabs and saliva, with a 5% higher sensitivity for the nasopharyngeal/oropharyngeal (92.2%) as compared to saliva (86.7%). While this might have been a liability in the context of individual diagnosis, this is not such a concern for mass screening, especially given the major advantage of the saliva sampling in terms of logistics. Previous meta-analyses of paired nasopharyngeal and saliva samples included less than 15 peer reviewed studies or preprints and reported average sensitivity of 91%, 85% and 83.4% in 4, 16 and 5 studies respectively ⁷³⁻⁷⁵. However, these studies used nasopharyngeal positivity as the reference, which did not seem relevant in our context.

To prevent a shortage of analytic reagents and to cut the costs necessarily associated to mass screening strategies, several recent publications have proposed mass testing methods based on saliva sampling either through extraction-free protocols⁷⁶⁻⁷⁸ or through pre-extraction sample pooling⁷⁹⁻⁸¹. In addition, sample pooling has gained a recognized interest for recurrent screening programs from the Centres of Disease Control recommendations⁸², and surveillance protocols implemented in higher education institutions across the world, e.g. the State University of New York (United States)⁸³, Liège University (Belgium)⁸⁴, Heidelberg University (Germany)⁸⁵ as well as at Nottingham University (United Kingdom)⁸⁶.

In conclusion, this meta-analysis conclusively demonstrates that saliva is as valid as nasopharyngeal sampling for the detection of SARS-CoV-2 infections in symptomatic as well as asymptomatic carriers. Contrarily to nasopharyngeal swabs, saliva sampling is simple, fast, non-invasive, inexpensive, painless and it thus uniquely applicable for surveillance, screening and diagnosis.

Acknowledgements

We wish to thank the FranceTest group for useful discussions and support: Drs. Philippe Froguel, Eric Karsenti, Franck Molina, Jean Rossier and Claire Wyart. We also thank Yannick Marie and Marc Sanson for setting up of the saliva tests at the ICM.

References

1. Ferretti L, Wymant C, Kendall M, et al. Quantifying SARS-CoV-2 transmission suggests epidemic control with digital contact tracing. *Science* 2020; **368**(6491).
2. Larremore DB, Wilder B, Lester E, et al. Test sensitivity is secondary to frequency and turnaround time for COVID-19 screening. *Sci Adv* 2020.
3. Lavezzo E, Franchin E, Ciavarella C, et al. Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo'. *Nature* 2020; **584**(7821): 425-9.
4. Xing Y, Wong GWK, Ni W, Hu X, Xing Q. Rapid Response to an Outbreak in Qingdao, China. *N Engl J Med* 2020; **383**(23): e129.
5. Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases. <https://www.who.int/publications-detail/laboratory-testing-for-2019-novel-coronavirus-in-suspected-human-cases-20200117> (accessed Jan. 3, 2021).
6. Overview of Testing for SARS-CoV-2 (COVID-19). https://www.cdc.gov/coronavirus/2019-ncov/hcp/testing-overview.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fhcp%2Fclinical-criteria.html (accessed Jan. 3, 2021).
7. Diagnostic testing and screening for SARS-CoV-2. <https://www.ecdc.europa.eu/en/covid-19/latest-evidence/diagnostic-testing> (accessed Jan. 4, 2021).
8. Detection of SARS-CoV-2 in saliva. https://www.has-sante.fr/jcms/p_3221176/fr/avis-n-2020-0081/ac/seap-du-27-novembre-2020-du-college-de-la-haute-autorite-de-sante-relatif-a-l-inscription-sur-la-liste-des-actes-et-prestations-mentionnee-a-l-article-l-162-1-7-du-code-de-la-securite-sociale-de-l-acte-de-detection-du-genome-du-virus-sars-cov-2-par-technique-rt-lamp-integree-sur-prelevement-salivaire-systeme-easycov accessed Jan. 4, 2021).
9. Siegler AJ, Hall E, Luisi N, et al. Willingness to Seek Diagnostic Testing for SARS-CoV-2 With Home, Drive-through, and Clinic-Based Specimen Collection Locations. *Open Forum Infect Dis* 2020; **7**(7): ofaa269.
10. Articles with the extracted data highlighted. <https://drive.google.com/drive/folders/1KkbSYdm9NYDfRIHVgaB4DDIm4gPn6f6w?usp=sharing> (accessed Jan. 4, 2021).
11. Woloshin S, Patel N, Kesselheim AS. False Negative Tests for SARS-CoV-2 Infection - Challenges and Implications. *N Engl J Med* 2020; **383**(6): e38.
12. Schwarzer G, Chemaitelly H, Abu-Raddad LJ, Rucker G. Seriously misleading results using inverse of Freeman-Tukey double arcsine transformation in meta-analysis of single proportions. *Res Synth Methods* 2019; **10**(3): 476-83.
13. Stijnen T, Hamza TH, Ozdemir P. Random effects meta-analysis of event outcome in the framework of the generalized linear mixed model with applications in sparse data. *Stat Med* 2010; **29**(29): 3046-67.
14. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ* 2003; **327**(7414): 557-60.
15. Agresti A, Coull BA. Approximate Is Better than "Exact" for Interval Estimation of Binomial Proportions. *The American Statistician* 1998; **52**(2): 119-26.
16. Team RC. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2020.
17. Balduzzi S, Rucker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. *Evid Based Ment Health* 2019; **22**(4): 153-60.
18. Aita A, Basso D, Cattelan AM, et al. SARS-CoV-2 identification and IgA antibodies in saliva: One sample two tests approach for diagnosis. *Clin Chim Acta* 2020; **510**: 717-22.
19. Altawalah H, AlHuraish F, Alkandari WA, Ezzikouri S. Saliva specimens for detection of severe acute respiratory syndrome coronavirus 2 in Kuwait: A cross-sectional study. *J Clin Virol* 2020; **132**: 104652.
20. Azzi L, Carcano G, Gianfagna F, et al. Saliva is a reliable tool to detect SARS-CoV-2. *J Infect* 2020; **81**(1): e45-e50.
21. Babady NE, McMillen T, Jani K, et al. Performance of Severe Acute Respiratory Syndrome Coronavirus 2 Real-Time RT-PCR Tests on Oral Rinses and Saliva Samples. *J Mol Diagn* 2020.
22. Barat B, Das S, Giorgi V, et al. Pooled Saliva Specimens for SARS-CoV-2 Testing. *medRxiv* 2020.

23. Berenger BM, Conly JM, Fonseca K, et al. Saliva collected in universal transport media is an effective, simple and high-volume amenable method to detect SARS-CoV-2. *Clin Microbiol Infect* 2020.
24. Bhattacharya D, Parai D, Rout UK, et al. Saliva for diagnosis of SARS-CoV-2: first report from India. *J Med Virol* 2020.
25. Binder RA, Alarja NA, Robie ER, et al. Environmental and Aerosolized Severe Acute Respiratory Syndrome Coronavirus 2 Among Hospitalized Coronavirus Disease 2019 Patients. *J Infect Dis* 2020; **222**(11): 1798-806.
26. Borghi E, Massa V, Carmagnola D, et al. Saliva sampling for chasing SARS-CoV-2: A Game-changing strategy. *Pharmacol Res* 2020: 105380.
27. Byrne RL, Kay GA, Kontogianni K, et al. Saliva Alternative to Upper Respiratory Swabs for SARS-CoV-2 Diagnosis. *Emerg Infect Dis* 2020; **26**(11): 2770-1.
28. Cassinari K, Alessandri-Gradt E, Chambon P, et al. Assessment of multiplex digital droplet RT-PCR as a diagnostic tool for SARS-CoV-2 detection in nasopharyngeal swabs and saliva samples. *Clin Chem* 2020.
29. Chau NVV, Thanh Lam V, Thanh Dung N, et al. The natural history and transmission potential of asymptomatic SARS-CoV-2 infection. *Clin Infect Dis* 2020.
30. Chen L, Zhao J, Peng J, et al. Detection of SARS-CoV-2 in saliva and characterization of oral symptoms in COVID-19 patients. *Cell Prolif* 2020; **53**(12): e12923.
31. Guclu E, Koroglu M, Yurumez Y, et al. Comparison of saliva and oro-nasopharyngeal swab sample in the molecular diagnosis of COVID-19. *Rev Assoc Med Bras (1992)* 2020; **66**(8): 1116-21.
32. Hanege FM, Kocoglu E, Kalciglu MT, et al. SARS-CoV-2 Presence in the Saliva, Tears, and Cerumen of COVID-19 Patients. *Laryngoscope* 2020.
33. Hanson KE, Barker AP, Hillyard DR, et al. Self-Collected Anterior Nasal and Saliva Specimens versus Health Care Worker-Collected Nasopharyngeal Swabs for the Molecular Detection of SARS-CoV-2. *J Clin Microbiol* 2020; **58**(11).
34. Hasanoglu I, Korukluoglu G, Asilturk D, et al. Higher viral loads in asymptomatic COVID-19 patients might be the invisible part of the iceberg. *Infection* 2020.
35. Iwasaki S, Fujisawa S, Nakakubo S, et al. Comparison of SARS-CoV-2 detection in nasopharyngeal swab and saliva. *J Infect* 2020; **81**(2): e145-e7.
36. Jamal AJ, Mozafarihashjin M, Coomes E, et al. Sensitivity of midturbinate versus nasopharyngeal swabs for the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). *Infect Control Hosp Epidemiol* 2020: 1-3.
37. Jamal AJ, Mozafarihashjin M, Coomes E, et al. Sensitivity of nasopharyngeal swabs and saliva for the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). *Clin Infect Dis* 2020.
38. Kandel C, Zheng J, McCreedy J, et al. Detection of SARS-CoV-2 from Saliva as Compared to Nasopharyngeal Swabs in Outpatients. *Viruses* 2020; **12**(11).
39. Kojima N, Turner F, Slepnev V, et al. Self-Collected Oral Fluid and Nasal Swab Specimens Demonstrate Comparable Sensitivity to Clinician-Collected Nasopharyngeal Swab Specimens for the Detection of SARS-CoV-2. *Clin Infect Dis* 2020.
40. Landry ML, Criscuolo J, Peaper DR. Challenges in use of saliva for detection of SARS CoV-2 RNA in symptomatic outpatients. *J Clin Virol* 2020; **130**: 104567.
41. Leung EC, Chow VC, Lee MK, Lai RW. Deep throat saliva as an alternative diagnostic specimen type for the detection of SARS-CoV-2. *J Med Virol* 2020.
42. Matic N, Stefanovic A, Leung V, et al. Practical challenges to the clinical implementation of saliva for SARS-CoV-2 detection. *Eur J Clin Microbiol Infect Dis* 2020.
43. McCormick-Baw C, Morgan K, Gaffney D, et al. Saliva as an Alternate Specimen Source for Detection of SARS-CoV-2 in Symptomatic Patients Using Cepheid Xpert Xpress SARS-CoV-2. *J Clin Microbiol* 2020; **58**(8).
44. Miguères M, Mengelle C, Dimeglio C, et al. Saliva sampling for diagnosing SARS-CoV-2 infections in symptomatic patients and asymptomatic carriers. *J Clin Virol* 2020; **130**: 104580.
45. Moreno-Contreras J, Espinoza MA, Sandoval-Jaime C, et al. Saliva Sampling and Its Direct Lysis, an Excellent Option To Increase the Number of SARS-CoV-2 Diagnostic Tests in Settings with Supply Shortages. *J Clin Microbiol* 2020; **58**(10).

46. Nagura-Ikeda M, Imai K, Tabata S, et al. Clinical Evaluation of Self-Collected Saliva by Quantitative Reverse Transcription-PCR (RT-qPCR), Direct RT-qPCR, Reverse Transcription-Loop-Mediated Isothermal Amplification, and a Rapid Antigen Test To Diagnose COVID-19. *J Clin Microbiol* 2020; **58**(9).
47. Pasomsub E, Watcharananan SP, Boonyawat K, et al. Saliva sample as a non-invasive specimen for the diagnosis of coronavirus disease 2019: a cross-sectional study. *Clin Microbiol Infect* 2020.
48. Procop GW, Shrestha NK, Vogel S, et al. A Direct Comparison of Enhanced Saliva to Nasopharyngeal Swab for the Detection of SARS-CoV-2 in Symptomatic Patients. *Journal of Clinical Microbiology* 2020; **58**(11): e01946-20.
49. Rao M, Rashid FA, Sabri F, et al. Comparing nasopharyngeal swab and early morning saliva for the identification of SARS-CoV-2. *Clin Infect Dis* 2020.
50. Sakanashi D, Asai N, Nakamura A, et al. Comparative evaluation of nasopharyngeal swab and saliva specimens for the molecular detection of SARS-CoV-2 RNA in Japanese patients with COVID-19. *J Infect Chemother* 2021; **27**(1): 126-9.
51. Senok A, Alsuwaidi H, Atrah Y, et al. Saliva as an Alternative Specimen for Molecular COVID-19 Testing in Community Settings and Population-Based Screening. *Infect Drug Resist* 2020; **13**: 3393-9.
52. Skolimowska K, Rayment M, Jones R, Madona P, Moore LSP, Randell P. Non-invasive saliva specimens for the diagnosis of COVID-19: caution in mild outpatient cohorts with low prevalence. *Clin Microbiol Infect* 2020; **26**(12): 1711-3.
53. SoRelle JA, Mahimainathan L, McCormick-Baw C, et al. Saliva for use with a point of care assay for the rapid diagnosis of COVID-19. *Clin Chim Acta* 2020; **510**: 685-6.
54. Sui Z, Zhang Y, Tu J, et al. Evaluation of saliva as an alternative diagnostic specimen source for SARS-CoV-2 detection by RT-dPCR. *J Infect* 2020.
55. Torres M, Collins K, Corbit M, et al. Comparison of saliva and nasopharyngeal swab SARS-CoV-2 RT-qPCR testing in a community setting. *J Infect* 2020.
56. Uwamino Y, Nagata M, Aoki W, et al. Accuracy and stability of saliva as a sample for reverse transcription PCR detection of SARS-CoV-2. *J Clin Pathol* 2021; **74**(1): 67-8.
57. Vaz SN, Santana DS, Netto EM, et al. Saliva is a reliable, non-invasive specimen for SARS-CoV-2 detection. *Braz J Infect Dis* 2020; **24**(5): 422-7.
58. Williams E, Bond K, Zhang B, Putland M, Williamson DA. Saliva as a Noninvasive Specimen for Detection of SARS-CoV-2. *J Clin Microbiol* 2020; **58**(8).
59. Wong S, Tse H, Siu HK, et al. Posterior oropharyngeal saliva for the detection of SARS-CoV-2. *Clin Infect Dis* 2020.
60. Wyllie AL, Fournier J, Casanovas-Massana A, et al. Saliva or Nasopharyngeal Swab Specimens for Detection of SARS-CoV-2. *N Engl J Med* 2020.
61. Yee R, Truong T, Pannaraj PS, et al. Saliva is a Promising Alternative Specimen for the Detection of SARS-CoV-2 in Children and Adults. *J Clin Microbiol* 2020.
62. Yokota I, Hattori T, Shane PY, et al. Equivalent SARS-CoV-2 viral loads between nasopharyngeal swab and saliva in symptomatic patients. *medRxiv* 2020: 2020.09.01.20186254.
63. Zhu J, Guo J, Xu Y, Chen X. Viral dynamics of SARS-CoV-2 in saliva from infected patients. *J Infect* 2020; **81**(3): e48-e50.
64. Caulley L, Corsten M, Eapen L, et al. Salivary Detection of COVID-19. *Ann Intern Med* 2020.
65. Otto MP, Darles C, Valero E, Benner P, Dutasta F, Janvier F. Posterior oropharyngeal saliva for the detection of SARS-CoV-2. *Clin Infect Dis* 2020.
66. Vogels CBF, Watkins AE, Harden CA, et al. SalivaDirect: A simplified and flexible platform to enhance SARS-CoV-2 testing capacity. *Med*.
67. Yokota I, Shane PY, Okada K, et al. Mass screening of asymptomatic persons for SARS-CoV-2 using saliva. *Clin Infect Dis* 2020.
68. Winnett A, Cooper MM, Shelby N, et al. SARS-CoV-2 Viral Load in Saliva Rises Gradually and to Moderate Levels in Some Humans. *medRxiv* 2020: 2020.12.09.20239467.
69. Mina MJ, Parker R, Larremore DB. Rethinking Covid-19 Test Sensitivity - A Strategy for Containment. *N Engl J Med* 2020; **383**(22): e120.

70. Arons MM, Hatfield KM, Reddy SC, et al. Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility. *N Engl J Med* 2020; **382**(22): 2081-90.
71. He X, Lau EHY, Wu P, et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. *Nat Med* 2020; **26**(5): 672-5.
72. Widders A, Broom A, Broom J. SARS-CoV-2: The viral shedding vs infectivity dilemma. *Infect Dis Health* 2020; **25**(3): 210-5.
73. Czumbel LM, Kiss S, Farkas N, et al. Saliva as a Candidate for COVID-19 Diagnostic Testing: A Meta-Analysis. *Front Med (Lausanne)* 2020; **7**: 465.
74. Kivela JM, Jarva H, Lappalainen M, Kurkela S. Saliva-based testing for diagnosis of SARS-CoV-2 infection: A meta-analysis. *J Med Virol* 2020.
75. Ricco M, Ranzieri S, Peruzzi S, et al. RT-qPCR assays based on saliva rather than on nasopharyngeal swabs are possible but should be interpreted with caution: results from a systematic review and meta-analysis. *Acta Biomed* 2020; **91**(3): e2020025.
76. Ott IM, Strine MS, Watkins AE, et al. Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices. *medRxiv* 2020.
77. Ranoa DRE, Holland RL, Alnaji FG, et al. Saliva-Based Molecular Testing for SARS-CoV-2 that Bypasses RNA Extraction. *bioRxiv* 2020: 2020.06.18.159434.
78. Vogels C.B.F. BDE, Wang J., Kalinich C.C., Ott I.M., Kudo E., Lu P., Venkataraman A., Tokuyama M., Moore A.J., Muenker M.C., Casanovas-Massana A., Fournier J., Bermejo S., Campbell M., Datta R., Nelson A., Yale IMPACT Research Team, Dela Cruz C., Farhadian S.F., Ko A.I., Iwasaki A., Hui P., Liu C., Wyllie A.L. and Grubaugh N.D. SalivaDirect: simple and sensitive molecular diagnostic test for SARS-Cov-2 surveillance. *medRxiv* 2020.
79. Gavars D, Gavars M, Perminovs D, et al. Saliva as testing sample for SARS-CoV-2 detection by RT-PCR in low prevalence community setting. *medRxiv* 2020: 2020.10.20.20216127.
80. Sahajpal NS, Mondal AK, Ananth S, et al. SalivaAll: Clinical validation of a sensitive test for saliva collected in healthcare and community settings with pooling utility for SARS-CoV-2 mass surveillance. *medRxiv* 2020: 2020.08.26.20182816.
81. Watkins A.E. EPF, Daniel M. Weinberger, Chantal B.F. Vogels, Doug E. Brackney, Arnau Casanovas-Massana, Melissa Campbell, John Fournier, Santos Bermejo, Rupak Datta, the Yale IMPACT Research Team, Charles S. Dela Cruz, Shelli F. Farhadian, Akiko Iwasaki, Albert I. Ko, Nathan D. Grubaugh, Anne L. Wyllie. Pooling saliva to increase SARS-CoV-2 testing capacity. *MedRxiv* 2020.
82. Interim Guidance for Use of Pooling Procedures in SARS-CoV-2 Diagnostic, Screening, and Surveillance Testing. <https://www.cdc.gov/coronavirus/2019-ncov/lab/pooling-procedures.html> (accessed Jan. 4, 2021).
83. SUNY COVID-19 Case Tracker. <https://www.suny.edu/COVID19-tracker/> (accessed Jan. 4, 2021).
84. Screening in practice. https://www.coronavirus.uliege.be/cms/c_12199182/en/screening-in-practice (accessed Jan. 4, 2021).
85. New Corona testing strategies for the general public. <https://www.virusfinder.de/en/> (accessed Jan. 4, 2021).
86. Fogarty A, Joseph A, Shaw D. Pooled saliva samples for COVID-19 surveillance programme. *Lancet Respir Med* 2020; **8**(11): 1078-80.

Table 1: Studies comparing SARS-CoV-2 detection in paired saliva and nasopharyngeal samples meeting inclusion criteria.

Reference	Number of tested individuals					Concordance	Reference : S+ ou N+	
	Saliva + Nasoph. +	Saliva - Nasoph. +	Saliva + Nasoph. -	Saliva - Nasoph. -	Total		Sensitivity of S	Sensitivity of N
	a	b	c	d	n=a+b+c+d		(a+c)/p	(a+b)/p
Aita	7	1	0	35	43	97.7%	87.5%	100.0%
Altawalah	287	57	18	529	891	91.6%	84.3%	95.0%
Azzi	22	4	33	54	113	67.3%	93.2%	44.1%
Babady	16	1	1	69	87	97.7%	94.4%	94.4%
Barat	30	7	1	421	459	98.3%	81.6%	97.4%
Berenger	52	11	6	6	75	77.3%	84.1%	91.3%
Bhattacharya	53	5	0	16	74	93.2%	91.4%	100.0%
Binder	10	1	1	7	19	89.5%	91.7%	91.7%
Borghi	79	28	7	187	301	88.4%	75.4%	93.9%
Byrne	12	2	0	96	110	98.2%	85.7%	100.0%
Cassinari	8	5	1	17	31	80.6%	64.3%	92.9%
Caulley	34	22	14	1869	1939	98.1%	68.6%	80.0%
Chau	19	0	1	7	27	96.3%	100.0%	95.0%
Chen	49	6	3	0	58	84.5%	89.7%	94.8%
Güçlü	23	4	4	33	64	87.5%	87.1%	87.1%
Hanega	29	9	0	0	38	76.3%	76.3%	100.0%
Hanson	75	5	6	268	354	96.9%	94.2%	93.0%
Hasanoglu	27	21	3	9	60	60.0%	58.8%	94.1%
Iwasaki	8	1	1	66	76	97.4%	90.0%	90.0%
Jamal 1	44	20	8	19	91	69.2%	72.2%	88.9%
Jamal 2	42	14	9	10	75	69.3%	78.5%	86.2%
Kandel	39	4	3	383	429	98.4%	91.3%	93.5%
Kojima	20	3	6	16	45	80.0%	89.7%	79.3%
Landry	28	5	2	89	124	94.4%	85.7%	94.3%
Leung	38	7	13	37	95	78.9%	87.9%	77.6%
Matic	15	6	1	52	74	90.5%	72.7%	95.5%
McCormick-Baw	47	2	1	106	156	98.1%	96.0%	98.0%
Migueres	34	7	3	79	123	91.9%	84.1%	93.2%
Moreno-Contreras	19	9	6	37	71	78.9%	73.5%	82.4%
Nagura-Ikeda	84	19	0	0	103	81.6%	81.6%	100.0%
Otto	45	0	4	43	92	95.7%	100.0%	91.8%
Pasomsub	16	3	2	179	200	97.5%	85.7%	90.5%
Procop	38	0	1	177	216	99.5%	100.0%	97.4%
Rao	73	11	76	57	217	59.9%	93.1%	52.5%
Sakanashi	15	0	4	9	28	85.7%	100.0%	78.9%
Senok	19	7	9	366	401	96.0%	80.0%	74.3%
Skolimowska	15	3	1	112	131	96.9%	84.2%	94.7%
Sorelle	32	7	0	44	83	91.6%	82.1%	100.0%
Sui	14	0	2	0	16	87.5%	100.0%	87.5%
Torres	46	54	8	835	943	93.4%	50.0%	92.6%
Uwamino	32	15	11	138	196	86.7%	74.1%	81.0%
Vaz	67	4	2	82	155	96.1%	94.5%	97.3%
Vogels	49	5	4	3776	3834	99.8%	91.4%	93.1%
Williams	33	6	1	49	89	92.1%	85.0%	97.5%
Wong	104	18	37	70	229	76.0%	88.7%	76.7%
Wyllie	34	9	13	13	69	68.1%	83.9%	76.8%
Yee	69	18	10	203	300	90.7%	81.4%	89.7%
Yokota	42	4	6	1872	1924	99.5%	92.3%	88.5%
Zhu	382	60	15	487	944	92.1%	86.9%	96.7%
Total	2375	510	358	13029	16272	92.6%	84.3%	89.0%

Figure 1: Evidence search and selection

Figure 2: Forest plot of the concordance between the results of RTqPCR tests on nasopharyngeal and saliva samples

The confidence intervals for each study are computed using the Clopper-Pearson method. Those for the overall estimates (fixed-effect or random-effect) are based on normal approximation. The blue box size is proportional to the number of positive tests. The red line corresponds to the value of the overall concordance of the random-effect model. This vertical line enables to locate the studies having an estimate concordance higher than 92.6%.

Figure 3: Forest plot of the sensitivity of RTqPCR test on saliva

The confidence intervals for each study are computed using the Clopper-Pearson method. Those for the overall estimates (fixed-effect or random-effect) are based on normal approximation. The blue box size is proportional to the number of positive tests. The difference between fixed-effect or random-effect overall sensitivity (respectively 84.3%, 86.7%) is low. The red line corresponds to the value of the overall sensitivity of the random-effect model. This vertical line enables to locate the studies having an estimate sensitivity higher than 86.7%. The heterogeneity estimator I^2 is equal to 80%, which means a higher level of heterogeneity.

Figure 4: Forest plot of the sensitivity of RTqPCR test on nasopharyngeal sample

The confidence intervals for each study are computed using the Clopper-Pearson method. Those for the overall estimates (fixed-effect or random-effect) are based on the normal approximation. The blue box size is proportional to the number of positive tests. The red line corresponds to the value of the overall sensitivity of the random-effect model. This vertical line enables to locate the studies having an estimate sensitivity higher than 92.2%. The heterogeneity estimator I^2 is equal to 84%, which means a higher level of heterogeneity.

Appendix Figure S1: Saliva sensitivity in each study as a function of SARS-CoV2 prevalence

Appendix Figure S2: Nasopharyngeal sample sensitivity in each study as a function of SARS-CoV2 prevalence

Figure S3: Prevalence in the population tested in France by symptomatic status

Sources: Points épidémiologiques hebdomadaires